Budget Impact model (BIM) of Polatuzumab + Rituximab + CHP for the treatment of 1L DLBCL

Looks good!

Looks good!
Scenario 1: With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
2023 2024 2025 2026 2027
Scenario 1: With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
Polatuzumab +
Rituximab +
Cyclophosphamide +
Doxorubicin +
Prednisone
Scenario 2: Without Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
"Rituximab +
Cyclophosphamide +
Doxorubicin +
Vincristine +
Prednisone" 		60.0% 30.0% 10.0% 5.0% 5.0%
Submit
>References:

[1] Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39(6):1103-1112. doi:10.1016/j.canep.2015.08.015

Budget Impact model (BIM) of Polatuzumab + Rituximab + CHP for the treatment of 1L DLBCL

Looks good!

Looks good!
Scenario 1: With Polatuzumab + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
2023 2024 2025 2026 2027
Polatuzumab +
Rituximab +
Cyclophosphamide +
Doxorubicin +
Prednisone
"Rituximab +
Cyclophosphamide +
Doxorubicin +
Vincristine +
Prednisone" 		60.0% 30.0% 10.0% 5.0% 5.0%
Submit
References:

[1] Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol. 2015;39(6):1103-1112. doi:10.1016/j.canep.2015.08.015